Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,878.88
+67.471.40%
Number of Gainers:33
Number of Losers:30
Number of Flat:2
PE:- -
High:4,911.82
Open:4,823.92
Low:4,820.11
Close:4,811.41
Volume:301.58M
Turnover:33.33B
Market Cap:8.72T
Float Cap:8.26T

Loading ...

Stocks to Watch Wednesday: Apple, Amazon, Fortum, Chewy & More

Dow Jones
·
Sep 09

AI, Smartphone Demand Boosting Foundry Growth as SMIC Gains on Samsung

Dow Jones
·
Sep 09

UK to Require Apple, Google to Block Nude Images on Children's Devices

MT Newswires Live
·
Sep 09

Uber initiated with an Outperform at Scotiabank

TIPRANKS
·
Sep 09

BEKE-W Completes US$1.98 Million Share Buyback on September 8

Stock News
·
Sep 09

Goldman Sachs Reaffirms Buy on ACM Research, Sets $166 Price Target

Stock News
·
Sep 09

Taiwan's Strict Reviews of iQiyi, Xiaohongshu, Luosifen, Zhang Xue Motorcycles, and Luckin Coffee Draw Rebuke as 'Unpopular Political Maneuvering'

Deep News
·
Sep 09

Uber is Seeking Around €4 Billion from Debut Euro Bond Sale - Bloomberg News

Reuters
·
Sep 09

Taiwan August Exports Hit Record Value on Solid AI Demand

Reuters
·
Sep 09

'The View' Host Joy Behar Finally Sells Hamptons House for About Half the Original Asking Price

Dow Jones
·
Sep 09

Zoom Sees FY Net Y400.00m

Dow Jones
·
Sep 09

Decoding Apple's Foldable Naming Puzzle: Duo, Ultra, or Fold?

Deep News
·
Sep 09

Nio's William Li urges focus on core business for next 3 years, teases major new models for 2027

CnEVPost
·
Sep 09

BridgeBio Posts Propel 3 Phase 3 Infigratinib Data in Children with Achondroplasia Presentation

Reuters
·
Sep 09

NIO Founder Predicts EVs Could Dominate 90% of New Car Sales by 2030, With Pure Electric Leading the Charge

Deep News
·
Sep 09

OpenAI Taps Samsung For Chips

Tech News Roundup
·
Sep 09

BridgeBio Says FDA Reviews NDA for Infigratinib in Achondroplasia

Reuters
·
Sep 09

BridgeBio Pharma Inc: Submitted an Nda to FDA for Oral Infigratinib in Achondroplasia and Anticipates a U.S. Launch in Mid-2027

THOMSON REUTERS
·
Sep 09

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 Propel 3 Trial

THOMSON REUTERS
·
Sep 09

BridgeBio Pharma, - Oral Infigratinib Shows Favorable Trends Versus Placebo in Sleep Apnea and Otitis Media at 52 Weeks

THOMSON REUTERS
·
Sep 09